REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
 
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > 5 Or 6 Peptide Repeating Units In Known Peptide Chain 5 Or 6 Peptide Repeating Units In Known Peptide Chain5 Or 6 Peptide Repeating Units In Known Peptide Chain patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021350 - Conjugates useful in the treatment of prostate cancer Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug ... 01/25/07 - 20070021349 - Orthogonally protected bifunctional amino acid The present invention concerns novel orthogonally protected amino acids, there production and use for the synthesis of binding compounds usable in the diagnosis and treatment of proliferative diseases, in particular tumor diseases. ... 01/11/07 - 20070010452 - Methionine aminopeptidase-2 inhibitors and methods of use thereof The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention. ... 01/04/07 - 20070004635 - Method of treating interferon non-responders using hcv protease inhibitor or a pharmaceutically acceptable salt, solvate or ester thereof. Optional combined administration of said at least one compound with an interferon or pegylated interferon and/or ribaviron is also contemplated. ... 01/04/07 - 20070004634 - Insulin and igf-1 receptor agonists and antagonists Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind ... 01/04/07 - 20070004633 - Use of peptidic conjugates for preparing compositions for alopecia preventive and curative treatment The invention relates to the use of peptidic conjugates containing Gly-His-Lys for producing dermatological or cosmetological compositions for stimulating hair growth or stopping hair fall. ... 12/28/06 - 20060293246 - Methods of modulating beta cell function Methods of modulating pancreatic function by modulating MCH signaling in a β cell. ... 12/28/06 - 20060293245 - P21 derived peptides and uses thereof The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving ... 12/21/06 - 20060287247 - Halogen-substituted thienyl compounds Halogen substituted thienyl compounds exhibit potential as nucleic acid (especially double stranded DNA) binders and as antibiotic compounds. A representative thienyl compound has the structure ... 12/14/06 - 20060281687 - Cyclin groove inhibitors A is (i) a natural or unnatural amino acid residue having a side chain comprising at least one H-bond acceptor moiety and at least one H-bond donor moiety, or a derivative thereof; or (ii) R(CO), wherein R is a C1-C24 hydrocarbyl group comprising at least one H-bond acceptor moiety and ... 12/14/06 - 20060281686 - Aza-peptides Provided are peptides comprising at least one azaamino acid and having β-sheet breaking ability, useful in the treatment and prevention of diseases such as alzheimer's disease, Dementia Pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and Vascular Dementia with amyloid angiopathy. ... 12/07/06 - 20060276403 - Agonist polypeptide of receptor for zot and zonulin Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide. ... 12/07/06 - 20060276402 - Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 The invention relates to synthetic peptide analogs of D-Arg-Oic-Pro-Gly-Phe and methods of their use to inhibit human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4. ... 11/30/06 - 20060270606 - Dolastatin 15 derivatives and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a β-hydroxylamino group, a hydrazido group, an ... 11/09/06 - 20060252698 - Compounds for inhibiting cathepsin activity The present invention provides methods of inhibiting cathepsin activity in a subject in need thereof comprising administering to said subject an effective amount of at least one compound of various formulae (e.g., formula I-XXVI) disclosed herein. The present invention also provides methods of treatment of various diseases utilizing the foregoing ... 10/26/06 - 20060241056 - Potent and specific immunoproteasome inhibitors Compounds and methods of selectively inhibiting an immunoproteasome are described. Also described are methods of treating a cancer, an inflammation, and/or an autoimmune disease and methods of suppressing endogenous antigenic peptide generation by administering to a subject in need of treatment thereof a therapeutic amount of an immunoproteasome specific inhibitor. ... 10/26/06 - 20060241055 - Peptides promoting cell adherence, growth and secretion The present invention provides specific peptides identified as having cell adhesion, growth, expression or secretion-enhancing activities. Many of the peptides of the invention may be produced in large quantity by such means as chemical synthesis or recombinant DNA methodology. They may be non-specifically adsorbed, or chemically attached to a surface ... 10/26/06 - 20060241054 - Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia According to the invention there is provided a method of treatment or prophylaxis of atherosclerosis, hypercholesterolemia or a cardiovascular disease associated with atherosclerosis, which method comprises administration of one or more Growth Hormone Releasing Peptides (GHRPs) to a patient in need of such treatment or prophylaxis. There are also provided ... 10/19/06 - 20060234945 - Ophthalmic therapeutic composition An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent ... 10/19/06 - 20060234944 - Beta-secretase inhibitors and methods of use Compounds inhibit memapsin 2 β-secretase activity and selectively inhibit memapsin 2 β-secretase activity relative to memapsin 1 β-secretase activity. The compounds are employed in methods to inhibit memapsin 2 β-secretase activity, in the treatment of Alzheimer's disease, in the inhibition of hydrolysis of a β-secretase site of a β-amyloid precursor ... 10/12/06 - 20060229252 - Antimicrobial hexapeptides The invention encompasses hexapeptides consisting of alternating hydrophobic residues (B) at positions 2, 4, and 6, hydrophilic, hydrophilic, charged residues (X) at positions 1 and 3, and a naphthylalanine (Nal), an aliphatic or aromatic residue (O) at position five, represented generally by the formula XBXBOB, which exhibit antimicrobial activity against ... 09/28/06 - 20060217317 - Activation of peptide prodrugs by hk2 The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods ... 09/21/06 - 20060211627 - Methods and compositions for derepression of iap-inhibited caspase The invention provides isolated agents having novel chemical structures and possessing superior activity as derepressors of IAP inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase. The invention further provides assay methods employing labeled compounds of the invention, especially fluorescent labeled compounds. ... 09/07/06 - 20060199771 - Stereoselective antifibrillogenic peptides and peptidomimetics thereof The present invention relates to antifibrillogenic agents for inhibiting amyloidosis and/or for cytoprotection for the treatment of amyloidosis disorders. These agents include peptides, isomers thereof and peptidomimetic compounds thereof. These agents comprise a peptide having a sequence identified from the glycosaminoglycan (GAG) binding region and the prot-prot interaction region of ... 09/07/06 - 20060199770 - Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry The present invention relates to functionalized carbon nanotubes, a process for preparing the same and their use, in particular in medicinal chemistry and more particularly in immunology. ... 08/31/06 - 20060194739 - Nociceptin-based analgesics The invention relates to a family of hexapeptide compounds exhibiting activity with regard to the ORL-1 receptor. The compounds share a general formula of Arg-Tyr-Tyr-Arg-Trp-Arg, and may be constructed having modifications or substitutions at any position, and may include modifications of the amino- and carboxy-termini of the hexapeptide. These compounds ... 08/17/06 - 20060183689 - Activation of peptide prodrugs by hk2 The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods ... 08/03/06 - 20060172949 - Compositions for preventing and treating digestive organs diseases The present invention provides a composition for safely and effectively preventing and treating digestive organs diseases, particularly, gastric ulcer, duodenal ulcer, gastritis, diarrhea, enteritis and the like. There is also provided a composition having a novel mechanism of action in order to solve the problems which was difficult to be ... 07/20/06 - 20060160746 - Amino acid and peptide conjugates of amiloride and methods of use thereof The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the ... 07/06/06 - 20060148718 - Conjugates useful in the treatment of prostate cancer Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug ... 07/06/06 - 20060148717 - Biocidal proteins Biocidal proteins capable of isolation from seeds have been characterized. The proteins have an amino acid sequence containing the common cysteine/glycine domain of Chitin-binding Plant Proteins but show substantially better activity against pathogenic fungi, a higher ratio of basic amino acids to acidic amino acids, and/or antifungal activity which results ... 06/29/06 - 20060142203 - Compositions and methods comprising protein activated receptor antagonists Compositions and methods comprising protein activated receptor antagonists are provided More particularly, the present invention relates to the use of proteins, peptides and biomolecules that bind to protein activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions ... 06/15/06 - 20060128631 - Peptides and derivatives thereof showing cell attachment, spreading and detachment activity The present invention relates to peptides and derivatives thereof showing cell attachment, spreading and detachment activity. Particularly, the present invention relates to the peptide NKDIL and EPDIM and derivatives thereof which promote the cell attachment activity through interaction with α3β1 integrin as a functional cell receptor and include aspartic acid ... 05/25/06 - 20060111301 - Methods for preventing and treating alzheimer's disease The invention relates to the use of a compound comprising the following amino acid sequence X1X2X3X4X5X6, wherein X1 is an amino acid, except of C, X2 is an amino acid, except of C, X3 is an amino acid, except of C, X4 is an amino acid, except of C, X5 ... 05/18/06 - 20060105959 - Organic compounds with biological action as thrombin inhibitors and use thereof The invention relates to biologically active molecules, which interact with thrombin and inhibit the same. The invention particularly relates to molecules of general fomula (I): Y1—(NH—X1—C═O)—(NH—X2—C═O)—(NH—X3—C═O)—(NH—X4—C═O)—(NH—X6—C═O) (NH—X6—C═O)—Y2, wherein Y1, Y2 and X1-6 have the meanings given in the description and N- or C-terminal abbreviated variations of said compounds and the ... 05/11/06 - 20060100156 - Cell nucleus-entering compositions A pharmaceutically acceptable composition and method for entering a cell nucleus utilizes a cell nucleus-entering polypeptide including at least one of amino acid sequence LKKTET, amino acid sequence LKKTNT or amino acid sequence KSKLKK, or a conservative variant thereof, linked to a physiologically active agent having at least one of ... 04/27/06 - 20060089310 - Treatment of infections and other disorders Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin β4, an isoform of Thymosin β4, oxidized Thymosin β4, or Tβ4 sulfoxide. ... 04/20/06 - 20060084612 - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-bromo- and α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and a protein kinase (serine/threonine and tyrosine kinases) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations ... 04/06/06 - 20060074028 - Reducing axon degeneration with proteasome inhibitors Reduced degeneration of an axon predetermined to be subject to degenerative neuropathy in a term patient is effected by contacting the axon in situ with an effective amount of a ubiquitin-proteasome system (UPS) inhibitor sufficient to reduce degeneration of the axon; and detecting a resultant reduction in the degeneration of ... 03/30/06 - 20060069035 - Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of ... 03/30/06 - 20060069034 - Antipathogenic benzamide compounds wherein at least one of the R1 groups is F, Cl, CN or CF3 and R2, R3, Y, Z, m, and n are as defined herein. ... 03/30/06 - 20060069033 - Use of poly-amminopyrrolecarboxamides alone or in combination with a cyclodextrin in the prophylaxis and treatment of animal parasitosis Use of distamycin, analogues and/or derivatives thereof in the manufacture of a pharmaceutical composition having activity against endoparasitosis in animals. ... 03/09/06 - 20060052310 - Regulation of substrate activity A method for regulating substrate activity in vivo is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment. ... 03/09/06 - 20060052309 - Use of convertase inhibitors in the treatment of fibrosis and scarring The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions. ... 01/19/06 - 20060014697 - Pharmaceutical compositions for prevention of overdose or abuse The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that ... 01/19/06 - 20060014696 - Modulators of beta-amyloid peptide aggregation comprising d-amino acids Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected ... 01/19/06 - 20060014695 - Hpma-polyamine conjugates and uses therefore The inventions provide compositions and methods for nucleic acid delivery comprising IIPMA conjugated to a polyamine. These compositions have the benefit of the steric hindrance of HPMA and the nucleic acid binding capability of a polyamine. Useful polyamines for this purpose include spermine, spermidine and their analogues, and DFMO. These ... 01/12/06 - 20060009393 - Immunogenic epitopes for fibroblast growth factors 5 (fgf-5) The present disclosure relates to peptides for use in immunotherapy of FGF-5 expressing tumors. In one example, the peptide is an HLA-A3 epitope (such as NTYASPRFK). In another example, the peptide is an HLA-A2 epitope (such as MLSVLEIFAV). Methods are provided for using such peptides (and corresponding nucleic acid molecules), ... 12/22/05 - 20050282756 - Oral delivery of peptide pharmaceutical compositions Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of ... 12/08/05 - 20050272662 - Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals The present invention provides a mixture of self-assembling peptide-amphiphiles with complementary charges whose design and function is patterned after proteins having biological functions. The oppositely charged peptide amphiphiles may be self-assembled by combining them in a charge equivalent ratio. Variations of structural peptide sequences in the oppositely charged peptide-amphiphiles enable ... 12/01/05 - 20050267039 - Il-16 antagonists In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and ... 11/24/05 - 20050261197 - Coffee bean extract, method of extraction and composition containing the same A composition containing genistein, flavionic acid, diadzien, diadzin, and a peptide having the amino acid sequence tyrosine-glycine-serine-arginine-serine, as well as pharmaceutical compositions prepared from such compositions possessing anti-inflammatory activity, and a method for isolating each compound and producing such a composition. A heating, extracting and condensing system that efficiently recovers ... 10/13/05 - 20050227925 - Compositions capable of reducing elevated blood urea concentration The invention includes a method of reducing urea concentration in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse ... 10/06/05 - 20050222044 - At4 receptor ligands as angiogenic, anti-angiogenic, and anti-tumor agents AT4 receptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. AT4 receptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, ... 10/06/05 - 20050222043 - Use of proteasome inhibitor in the treatment of fibrotic diseases The invention relates to the use of at least one proteasome inhibitor, preferably in the form of a threonine protease inhibitor, in the treatment of fibrotic diseases, espeially fibrotic diseases of the cardiovascular system. ... 09/29/05 - 20050215484 - Di-, tri-, and tetra-peptides having antiangiogenic activity Compounds having the formula (SEQ ID NO: 1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis. ... 09/15/05 - 20050203027 - Inhibitors of dipeptidylpeptidase iv The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes ... 09/08/05 - 20050197298 - Tryptophanyl-trna synthetase-derived polypeptides useful for the regulation of angiogenesis An isolated, water-soluble polypeptide fragment of human tryptophanyl-tRNA synthetase is useful for the inhibition of angiogenesis. The polypeptide has the amino acid residue sequence shown in SEQ ID NO: 7, SEQ ID NO: 12, or an angiogenesis inhibiting fragment thereof, the fragment including at least one of amino acid residue ... 08/25/05 - 20050187164 - Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof The invention relates to peptides of formula (I) R-V1-Ala2-His3-X4-Y5-Trp5-NH2 wherein R represents a hydrogen atom or a protective group which can be chosen from among a benzoyl group, a tosyl group, a benzene sulfonyl group, a benzyloxycarbonyl group or a pyridinepropionyl group; V represents a natural amino acid or not ... 08/11/05 - 20050176648 - Novel peptides as ns3-serine protease inhibitors of hepatitis c virus The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 08/11/05 - 20050176647 - Novel hairpin polyamide It is intended to provide a pyrrole-imidazole polyamide type functional molecule having enhanced abilities of alkylating DNA and recognizing a sequence, compared with the existing functional molecules of this type, for a specific base sequence occurring on DNA. A hairpin polyamide having an alkylation site via a vinyl linker at ... 08/04/05 - 20050171021 - Buffered drug formulations for transdermal Buffered drug formulations for transdermal electrotransport delivery are disclosed. The formulations utilize a dipeptide as a buffer and allow for more efficient electrotransport delivery of drugs, e.g., polypeptide drugs, via the transdermal route. ... 07/28/05 - 20050164952 - Delivery system for growth hormone releasing peptides A system for delivering a growth hormone releasing peptide including a peptide, or a pharmaceutically acceptable salt form thereof, alternatively conjugated to a polymer via a biodegradable bond and dissolved in a liquid medium. Because extra-cellular fluids in vivo provide the appropriate environment to efficiently degrade peptides, the growth hormone ... 07/28/05 - 20050164951 - Inhibitors for the soluble epoxide hydrolase Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases. ... 07/28/05 - 20050164950 - Orally administered small peptides synergize statin activity This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention ... 07/07/05 - 20050148516 - Sugar transferase gnt-v having angiogenic effect The present invention provides a peptide or protein having a neovascularization action and containing a basic amino acid cluster region of β1,6-N-acetylglucosaminyltransferase, a neovascularization accelerator containing the above-mentioned peptide or protein, a method of screening an inhibition substance for the above-mentioned peptide or protein, and a neovascularization inhibitor containing this ... 07/07/05 - 20050148515 - Growth hormone releasing peptides Disclosed are peptide and peptidomimetic compounds generally according to formula (I), and pharmaceutically acceptable salts thereof, that are useful as GHRP analogs: R1-A2-A3-A4-A5-R2 (I) or a pharmaceutically acceptable salt thereof, wherein: A1 is Aib, Apc or Inp; A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp; A3 is ... 06/30/05 - 20050143314 - Compositions and methods to treat recurrent medical conditions The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction. ... 06/30/05 - 20050143313 - Novel peptide, method of production thereof, and pharmaceutical composition containing the same A biologically active peptide having the amino acid sequence tyrosine-glycine-serine-arginine-serine, as well as compositions prepared from such peptide, possessing anti-cancer activity and anti-inflammatory activity, and a method for producing such a peptide and composition. The peptide is obtained by utilizing a heating, extracting and condensing system that efficiently recovers the ... 06/30/05 - 20050143312 - Compositions and methods for promoting myocardial and peripheral angiogenesis Methods, compositions and devices are disclosed for use in growing new blood vessels to restore or improve blood flow to ischemic tissues and organs of the body. Compositions comprising IGD peptides, particularly GGIGDGG, are able to induce migration in human endothelial cells and promote vessel formation in an in vitro ... 06/23/05 - 20050137138 - E2f activity-inhibiting compound E2F-inhibiting compounds are represented by the general formula: R1-A-R2 wherein A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of the E2F family), which are useful as a therapeutic agent of ... 06/16/05 - 20050130903 - Therapeutic agents and methods of use thereof for the modulation of angiogenesis The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to ... 06/16/05 - 20050130902 - Peptide compounds for counteracting reactive oxygen species and free radicals The invention provides compositions comprising isolated peptide compounds, which upregulate expression of a gene encoding an antioxidative anzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals. The composition may be used to treat or prevent diseases and conditions characterized ... 06/09/05 - 20050124551 - Use of kpv tripeptide for dermatological disorders The present invention is directed to a prevention and treatment for dermatological disorders. One aspect of this invention involves a dermatological treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), or SYSMEHFRWGKPV ... 06/02/05 - 20050119188 - Method of treating breast cancer A method of treating breast cancer is disclosed. The method comprises administering an FTI, at least one antihormonal agent (e.g., an aromatase inhibitor, an antiestrogen, and an LHRH analogue), optional chemotherapeutic agents (e.g., Trastuzumab), and optional radiation. For example, the treatment of breast cancer using the FTI and Anastrozole is ... 06/02/05 - 20050119187 - Anti-fibril peptides The preparation of amyloid fibril blocker peptides based on amyloid peptide hydrophobic core Aβ16-20 is described. These blocker peptides containing sterically ... ### FreshPatents.com Support - Terms & Conditions |